双Orexin受体拮抗剂市场报告：2031 年趋势、预测与竞争分析

全球双Orexin受体拮抗剂市场前景光明，医院和诊所市场以及零售药局市场都蕴藏着巨大的机会。预计2025年至2031年期间，全球双Orexin受体拮抗剂市场的复合年增长率将达到7.8%。这个市场的主要驱动因素包括失眠症盛行率的上升、对更优治疗方案的需求不断增长，以及人们对睡眠障碍的认识不断提高。

• Lucintel 预测，根据类型，daridolexant 预计在预测期内实现最高成长。
• 从应用来看，医院和诊所预计将经历高速成长。
• 根据地区，预计北美将在预测期内实现最高成长。

双Orexin受体拮抗剂市场的新趋势

双Orexin受体拮抗剂市场正见证一系列新兴趋势，这得益于药理学的进步、睡眠障碍盛行率的上升以及消费者偏好的变化。随着对Orexin受体认知的不断加深，新的适应症和剂型正在被研究，以满足各种患者的需求。这些趋势正在引领DORA市场的未来，并创造成长机会。

• 个人化睡眠疗法：DORA 的一个发展方向是迈向个人化睡眠疗法。随着研究的进步，药物正日益个人化，以满足患者的需求，并考虑到患者的基因组成、睡眠行为以及对各种疾病的易感性。这一趋势使得更有效、更个人化的治疗能够解决睡眠障碍的根本原因，从而使基于 DORA 的药物更加有效和安全。因此，个人化疗法将成为 DORA 市场的重要组成部分，为患者提供量身定制的解决方案。
• 非成瘾性治疗：对非成瘾性睡眠药物日益增长的需求推动了 DORA 市场的发展。与镇静剂和苯二氮平类催眠药不同，DORA 不会产生依赖性或戒断症状的风险。这使得 DORA 对寻求长期治疗睡眠障碍且无成瘾风险的患者越来越有吸引力。随着人们对使用传统睡眠药物相关风险的认识不断提高，对 DORA 的需求可能会增长，尤其是在那些对药物依赖性担忧较高的国家。
• 睡眠障碍的联合治疗：人们越来越关注将双Orexin受体拮抗剂与其他药物类别联合使用，以治疗失眠和发作性睡病等复杂的睡眠障碍。将双食慾素受体拮抗剂（DORA）与抗忧郁症和抗精神病药物等其他药物合併使用，可望提高整体治疗效果，并同时治疗多种潜在疾病。这一趋势有望为 DORA 市场带来新的治疗机会，为患有更严重健康问题的患者提供完整的解决方案。
• DORA 对其他疾病的研究：儘管 DORA 主要用于治疗睡眠障碍，但目前也存在着探索其在其他神经系统疾病中的治疗潜力的趋势。目前正在进行研究，以探索如何利用 DORA 治疗焦虑症、忧郁症，甚至阿兹海默症疾病。 DORA 能够调节与觉醒和唤醒有关的Orexin受体，使其成为更广泛治疗的良好候选药物。这一趋势可能为 DORA 创造更大的市场，并使其成为神经系统领域的多功能药物。
• 更多监管核准和临床试验：随着多效合成酶抑制剂 (DORA) 不断证明其在治疗睡眠障碍方面的有效性，越来越多的临床试验正在进行，监管机构也正在核准更多 DORA 药物。随着人们对改善睡眠品质和应对全球睡眠障碍发病率快速上升的兴趣日益浓厚，越来越多的製药公司正在投资基于 DORA 的疗法。随着新产品的涌现和临床数据的积累，这一趋势将增加治疗选择，并推动市场进一步成长。

双Orexin受体拮抗剂市场的新趋势，例如对个人化睡眠治疗、非成瘾性治疗和联合疗法的研究，正在显着改变行业格局。这些趋势预示着睡眠障碍治疗将持续朝着更有效率、更安全的个人化方向发展，为未来几年 DORA 市场的成长和创新奠定了基础。

双Orexin受体拮抗剂市场的最新趋势

近年来，双Orexin受体拮抗剂市场取得了显着进展，这得益于睡眠障碍研究活动的活性化、监管部门的核准以及製剂的改进。所有这些进展都提高了基于双食慾素受体拮抗剂（DORA）疗法的疗效，并为患有睡眠障碍和其他继发性併发症的患者提供了新的治疗途径。以下是重塑市场的五个最重要的新兴市场发展：

• FDA核准Suvorexant：2014 年，美国FDA核准Suvorexant（Balsara）是 DORA 市场的一个重要里程碑。作为该类别的首个治疗药物，Balsara 现已成为失眠症患者最广泛的治疗选择之一。这项核准为 DORA 的进一步开发铺平了道路，进一步凸显了Orexin受体拮抗剂在诱导睡眠方面的功效。 Balsara 的成功促使人们进一步研究其他有前景的 DORA 药物，从而增加了失眠和睡眠障碍的治疗方法。
• 正在研发的DORA药物：许多製药公司正在开发新型双Orexin受体拮抗剂，以满足日益增长的睡眠药物需求。这些药物正在进行临床试验，以验证其在治疗失眠、发作性睡病和其他睡眠相关疾病方面的安全性和有效性。随着旨在提高DORA疗效并减少其副作用的研究不断进行，这些新药预计将对市场产生重大影响，并为患者提供更多治疗选择。
• DORA 全球可近性不断扩大：随着越来越多的国家核准DORA，DORA 的全球市场正在扩大。 Suvorexant 已在多个国家获批，随着临床数据的积累，更多基于 DORA 的药物有望获得批准。这一增长将有助于满足全球对安全有效的睡眠药物日益增长的需求。预计 DORA 药物的可近性将增强市场竞争力，并改善全球消费者的治疗效果。
• 重视非成瘾性疗法：随着人们对传统镇静剂危害的担忧日益加深，人们越来越重视开发非成瘾性助眠剂。 DORA 在这方面处于领先地位，因为它们不会像其他睡眠药物那样带来成瘾风险。随着患者和医疗保健专业人员都在寻求更安全、更长期的失眠和其他睡眠障碍治疗方法，对基于 DORA 的治疗方法的需求也日益增长。
• 拓展 DORA 适应症的研究：除睡眠障碍外，DORA 的适应症研究正在加速进行。其作为焦虑症和忧郁症神经精神疾病以及阿兹海默症神经退化性疾病的治疗潜力正在被探索。如果这些研究取得成功，DORA 的治疗领域将大幅扩展，为多种疾病的治疗开闢新的典范。应用范围的拓展有望成为市场扩张和技术创新的驱动力。

双Orexin受体拮抗剂市场的重大进展，包括监管部门的核准、开发新药以及全球药局的扩大，必将推动睡眠障碍治疗领域的进一步发展和创新。随着更多药物上市以及更多适应症的研究，DORA 市场将大幅扩张，并惠及病患和製药公司。

目录

第一章执行摘要

2. 全球双Orexin受体拮抗剂市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球双Orexin受体拮抗剂市场趋势（2019-2024）及预测（2025-2031）
• 按类型
  • 舒沃雷生
  • 柠檬黄素
  • 达利多雷生
• 按用途
  • 医院和诊所
  • 零售药局
  • 其他的

第四章2019年至2031年区域市场趋势与预测分析

• 按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按类型
  • 按用途
  • 按地区
• 全球双Orexin受体拮抗剂市场的新趋势
• 战略分析
  • 新产品开发
  • 全球双Orexin受体拮抗剂市场产能扩张
  • 全球双Orexin受体拮抗剂市场的合併、收购与合资企业
  • 认证和许可

第七章主要企业简介

• Merck
• Eisal
• Idorsia
• Takeda

The future of the global dual orexin receptor antagonist market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global dual orexin receptor antagonist market is expected to grow with a CAGR of 7.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of insomnia, the increasing demand for better treatments, and the growing awareness of sleep disorders.

• Lucintel forecasts that, within the type category, daridorexant is expected to witness the highest growth over the forecast period.
• Within the application category, hospital & clinic is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market is seeing a number of emerging trends, fueled by advancements in pharmacology, the rising incidence of sleep disorders, and changing consumer preferences. As knowledge about orexin receptors grows, new indications and drug formulations are being investigated to address various patient needs. These trends are guiding the future of the DORA market and creating opportunities for increased growth.

• Customized Sleep Therapies: A trend in DORA's direction is seen to move toward customized sleep therapies. With growing advancements in research, more medicines are being made personalized to fit patients' requirements specifically, considering their genetic structure, sleep behaviors, and predisposition to various medical conditions. This trend is making it possible to have more efficient and personalized treatments that address the underlying causes of sleep disorders, making DORA-based medicines more effective and safer. Consequently, personalized therapies will be a major component of the DORA market, providing patient-specific solutions.
• Non-Habit-Forming Treatments: Rising demand for non-habit-forming sleep medications is creating a drive in the DORA market. Unlike sedatives and benzodiazepines, DORAs have no risk of dependence or withdrawal symptoms associated with them. This has rendered DORAs increasingly appealing to patients who desire long-term remedies for sleep disorders without the risk of addiction. As people become more aware of the risks associated with the use of conventional sleep medicines, demand for DORAs will increase, particularly in countries where there is high concern about dependency on medications.
• Combination Therapies for Sleep Disorders: There is increasing interest in combining dual orexin receptor antagonists with other drug classes to treat complicated sleep disorders, such as insomnia and narcolepsy. By combining DORAs with other therapeutic drugs, such as antidepressants or antipsychotics, scientists are hoping to enhance the overall effectiveness of treatments and treat multiple underlying conditions at once. This trend will lead to new opportunities for therapy in the DORA market and give patients with more severe health problems complete solutions.
• DORA Research for Other Disorders: Even though DORAs are utilized mostly for sleep disorders, a trend is observed towards exploring their therapeutic potential in other neurological diseases. Studies are in progress to discover how to use DORAs in the treatment of diseases such as anxiety, depression, and even Alzheimer's. Since DORAs can modulate orexin receptors, which are involved in wakefulness and arousal, they are a strong contender for a broader therapy. This trend could make the market for DORAs much larger and position them as multi-purpose drugs within the neurological arena.
• More Regulatory Approvals and Clinical Trials: As DORAs continue to show their efficacy in the treatment of sleep disorders, more clinical trials are being undertaken and regulatory agencies are approving more DORA drugs. The growing interest in bettering the quality of sleep and tackling the worldwide surge in sleep disorders is causing more pharmaceutical firms to invest in DORA-based therapy. This trend should result in an increase in treatment options, fueling further market growth as new products emerge and clinical data continue to accrue.

The new trends in the dual orexin receptor antagonist market, including personalized sleep treatments, non-addictive treatments, and studies on combination treatments, are greatly transforming the industry landscape. These trends are indicative of a continued move towards more efficient, safer, and personalized treatments for sleep disorders, setting the DORA market up for future growth and innovation over the next few years.

Recent Developments in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market witnessed significant progress in recent years, fueled by rising research activity in sleep disorders, approvals from the regulatory authorities, and advancements in formulations. All these advances have enhanced the efficacy of DORA-based treatments, presenting patients suffering from sleep disorders and other secondary complications with new avenues for treatment. Five of the most significant developments that are remaking the market are discussed below.

• FDA Approval of Suvorexant: The US FDA approval of Suvorexant (Balsara) in 2014 was a major benchmark for the DORA market. As the inaugural drug of this category, Balsara is now one of the largest treatment options available to patients of insomnia. This endorsement has opened the door to additional development of DORAs and has highlighted further the effectiveness of orexin receptor antagonism in inducing sleep. The success of Balsara has encouraged further research into other promising DORA drugs, increasing the treatments available for insomnia and sleep disorders.
• Pipeline DORA Drugs in Development: A number of pharmaceutical firms are developing novel Dual Orexin Receptor Antagonists to meet the increasing demand for sleep medicines. The drugs are being tested in clinical trials to determine their safety and effectiveness in the treatment of diseases such as insomnia, narcolepsy, and other sleep-related disorders. With constant research aimed at enhancing the efficacy of DORAs and reducing side effects, these new drugs have the promise to make a significant impact on the market and offer more treatment alternatives for patients.
• DORA Availability Widening Globally: With increased countries approving DORA drugs, the global market for these drugs is widening. Suvorexant has already been licensed in some countries, and more DORA-based medications are likely to be licensed as clinical data continue to accumulate. This growth is assisting in meeting increasing global demand for safe and effective sleep medications. Greater availability of DORA medications will be expected to enhance market competitiveness and make for improved treatment for consumers globally.
• Emphasis on Non-Habit-Forming Therapies: As concerns about the dangers of conventional sedatives continue to grow, efforts are focused on creating non-habit-forming sleep aids. DORAs, which pose no risk of dependence like other sleeping medications, lead the charge. Patients and healthcare professionals alike are increasingly looking for safer long-term cures for insomnia and other sleep disorders, and recognizing this, demand for DORA-based therapies is increasing.
• Expanded Indications Research for DORAs: Research on the application of DORAs for indications other than sleep disorders is picking up speed. Investigations are looking into the possibility of these drugs being used to treat neurological and psychiatric diseases like anxiety, depression, and neurodegenerative conditions like Alzheimer's. If successful, these studies can drastically expand the therapeutic horizon for DORAs and result in new paradigms for the treatment of several diseases. This broadened application would fuel market expansion and innovation.

The major advancements in the dual orexin receptor antagonist market, such as regulatory approval, new drug development, and expanded global access, are leading the way towards additional growth and innovation in treating sleep disorders. With more drugs coming to the market and further research into more indications, the DORA market is set for dramatic expansion, to the advantage of both patients and pharmaceutical firms.

Strategic Growth Opportunities in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market offers many strategic growth opportunities in key applications, fueled by a growing awareness of sleep disorders and a growing emphasis on neurological health. These opportunities range across a number of therapeutic areas, from sleep disorders to psychiatric and neurological disorders, and are likely to define the future of the market.

• Growth in Emerging Markets: Emerging markets in Asia, Latin America, and Africa provide ample growth opportunities for the DORA market. With growing awareness of sleep disorders and increasing disposable incomes, demand for effective sleep aids is on the rise. Companies can customize their products to suit the particular requirements of these markets, increasing their reach through localized marketing channels and distribution networks.
• Expansion in Sleep Disorder Treatment: With the increasing incidence of sleep disorders such as insomnia, narcolepsy, and sleep apnea across the world, the market for dual orexin receptor antagonists is likely to grow. By targeting the enhancement of availability and affordability of DORA drugs for the treatment of sleep disorders, pharmaceutical companies can capitalize on this expanding market, particularly as more people look for non-habit-forming, effective treatments.
• Targeting Mental Health Disorders: Investigations into the potential application of DORAs in treating mental health disorders, including depression and anxiety, are creating new opportunities for market expansion. With the increasing demand for treatments that target both sleep disorders and psychiatric disorders, DORAs may provide a two-pronged approach to patient treatment. This potential makes DORAs central drugs for the treatment of sleep and mental health disorders.
• Emphasis on Personalized Medicine: Personalized medicine is taking center stage in the healthcare sector, and the DORA market is no different. By creating customized treatments that take into consideration patient-specific factors, including genetic factors and lifestyle, firms are able to maximize the safety and effectiveness of DORA-based medicines. This trend will propel market growth as patients are increasingly looking for customized treatment solutions that meet their specific needs.
• Combination Therapies with Wider Market Opportunities: Combination therapies of DORAs and other drug types, like antidepressants or antipsychotics, have considerable growth opportunities. These therapies have the goal to treat multiple basic conditions, for example, sleep disorders, anxiety, and depression, within one treatment protocol. Through the presentation of comprehensive remedies, combination therapies of DORAs have a wider market scope and can create new therapeutic avenues for complex diseased patients.

Strategic opportunities for growth in the dual orexin receptor antagonist market, fueled by emerging markets, mental health uses, personalized medicine, and combination therapies, will dramatically reshape the market landscape. Companies that target these opportunities will be well-positioned to succeed in this dynamic and fast-growing market.

Dual Orexin Receptor Antagonist Market Driver and Challenges

The dual orexin receptor antagonist market is influenced by several drivers and challenges such as technological innovations, economic considerations, and regulatory aspects. While they drive the market growth, they also pose challenges that have to be tackled by manufacturers. Through knowledge of these major drivers and challenges, companies can set themselves up for success.

The factors responsible for driving the dual orexin receptor antagonist market include:

1. Increasing Incidence of Sleep Disorders: With the global incidence of sleep disorders, including insomnia and narcolepsy, on the rise, there is a growing need for effective treatments such as dual orexin receptor antagonists. DORAs offer a novel and non-habit-forming alternative to conventional sedatives, fueling market growth.

2. Drug Formulation Innovations: Advances in drug technology are making it possible to develop more potent and targeted DORA-based medications. Innovative formulations that enhance the safety and effectiveness of the drugs are drawing in customers and healthcare professionals, driving the market further.

3. Increased Emphasis on Mental Health: The increased emphasis on mental health and its relationship with sleep disorders is fueling demand for DORA therapies. Addressing both sleep and psychological ailments, DORAs are now being recognized as a feasible treatment option, which is broadening their market scope.

4. Increasing Healthcare Spending: Increasing healthcare spending worldwide is driving the growth of the DORA market, as patients are increasingly opting for medical treatment for their sleep disorders. With increasing disposable income, patients are becoming more inclined to spend money on sophisticated treatments that provide long-term results.

5. Enlarging Clinical Research: Continuous clinical research into the therapeutic potential of DORAs for other neurological and psychiatric disorders, as well as sleep disorders, is a major growth driver for the market. With new indications for DORAs arising, the market for these medications is likely to grow.

Challenges in the dual orexin receptor antagonist market are:

1. Regulatory Hurdles: The regulatory process for the approval of DORA drugs is time-consuming and complex, especially in countries with strict pharmaceutical regulations. Companies need to overcome these issues to market their drugs on time.

2. Emerging Markets' Price Sensitivity: With demand for DORAs growing, price sensitivity is an area of difficulty, particularly in the emerging markets. Firms need to juggle the accessibility of their product alongside ensuring the same high level of quality and efficacy.

3. Alternative Treatment Competition: The DORA market competes with alternative treatments for sleep disorders, including benzodiazepines, melatonin, and other sedatives. Companies need to differentiate DORA-based therapies from these alternatives to remain competitive.

The challenges and drivers affecting the dual orexin receptor antagonist market mirror the dynamic nature of the sector. Although increased awareness, formulation advancements, and rising healthcare investment are fueling growth, regulatory barriers and price sensitivity remain current challenges. By addressing these variables, companies can more effectively deal with the intricacies of the market and take advantage of emerging opportunities.

List of Dual Orexin Receptor Antagonist Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dual orexin receptor antagonist companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dual orexin receptor antagonist companies profiled in this report include-

• Merck
• Eisal
• Idorsia
• Takeda

Dual Orexin Receptor Antagonist Market by Segment

The study includes a forecast for the global dual orexin receptor antagonist market by type, application, and region.

Dual Orexin Receptor Antagonist Market by Type [Value from 2019 to 2031]:

• Suvorexant
• Lemborexant
• Daridorexant

Dual Orexin Receptor Antagonist Market by Application [Value from 2019 to 2031]:

• Hospital & Clinic
• Retail Pharmacies
• Others

Dual Orexin Receptor Antagonist Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Dual Orexin Receptor Antagonist Market

The market for dual orexin receptor antagonist (DORA) has been expanding very quickly as a result of increasing interest in sleep disorders like insomnia and other neurological conditions associated with it. This category of drugs, acting on the orexin receptors involved in wakefulness regulation, is gaining popularity across the world because of its efficiency in inducing sleep without side effects compared to conventional sedatives. Major developments in the DORA market have been noted in key pharma markets such as the United States, China, Germany, India, and Japan, where research, clinical trials, and product approvals remain to define the market scenario.

• United States: In the United States, the market for dual orexin receptor antagonist has experienced considerable growth, especially with the regulatory approval of products such as Suvorexant (Balsara), the first DORA to be approved by the FDA for the treatment of insomnia. An increased need for effective treatments, fueled by the rising incidence of sleep disorders, has driven further interest in DORAs. U.S. market is marked by swift uptake of novel sleep aids, with continuous research aimed at enhancing the safety and effectiveness of the drugs. The regulatory environment is favorable, offering a clear line for further DORA drugs to come into the market.
• China: China is experiencing swift growth in the market for DORA as awareness about sleep disorders rises and more attention is being focused on mental health. The Chinese government has been investing in healthcare infrastructure, and increasing numbers of people are looking for treatments for insomnia and associated conditions. Although DORAs are relatively new to the market, consumers are increasingly interested in innovative sleep aids. Clinical trials and research are ongoing, and the market is likely to grow as the demand for safe and effective treatment for sleep disorders grows nationwide.
• Germany: Germany's DORA market is expanding steadily, with growing awareness of sleep disorders such as insomnia and narcolepsy. With the healthcare system providing significant support for mental health conditions, Germany has emerged as a leading market for the uptake of new treatments. Regulatory approvals for DORAs like Suvorexant and other upcoming drugs have improved treatment options for patients. Germany is targeting the betterment of sleeping quality and encouragement of safer alternatives to conventional sedatives. Having robust pharmaceutical corporations in Germany enhances ongoing research and development in this sector.
• India: In India, the DORA market remains nascent with very limited presence of orexin receptor-targeted drugs for sleeping disorders. Nonetheless, with the rising prevalence of insomnia and increased awareness of mental illness, there is a growing demand for successful treatments. The market is dominated by the embracement of Western medicine, yet there is a desire for cheaper drugs. Regulatory authorities in India are considering the approval of DORAs, and the market is expected to expand as knowledge of the advantages of DORA-based therapies spreads among the healthcare community and consumers.
• Japan: Japan has experienced strong growth in the DORA market, especially with the rising incidence of sleep disorders due to lifestyle and aging populations. Japanese pharmaceutical firms are at the forefront of creating DORA-based treatments, including the approval of Suvorexant. The need for safe and non-habit-forming sleep aids is increasing, and DORAs are a very promising treatment option. Japan's strong healthcare system and regulatory environment facilitate the ongoing development of this market. The emphasis is on providing effective treatments that ensure healthy sleep without the threat of dependence.

Features of the Global Dual Orexin Receptor Antagonist Market

Market Size Estimates: Dual orexin receptor antagonist market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Dual orexin receptor antagonist market size by type, application, and region in terms of value ($B).

Regional Analysis: Dual orexin receptor antagonist market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the dual orexin receptor antagonist market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dual orexin receptor antagonist market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dual orexin receptor antagonist market by type (suvorexant, lemborexant, and daridorexant), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dual Orexin Receptor Antagonist Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Dual Orexin Receptor Antagonist Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Dual Orexin Receptor Antagonist Market by Type
  • 3.3.1: Suvorexant
  • 3.3.2: Lemborexant
  • 3.3.3: Daridorexant
• 3.4: Global Dual Orexin Receptor Antagonist Market by Application
  • 3.4.1: Hospital & Clinic
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Dual Orexin Receptor Antagonist Market by Region
• 4.2: North American Dual Orexin Receptor Antagonist Market
  • 4.2.1: North American Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.2.2: North American Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.3: European Dual Orexin Receptor Antagonist Market
  • 4.3.1: European Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.3.2: European Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.4: APAC Dual Orexin Receptor Antagonist Market
  • 4.4.1: APAC Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.4.2: APAC Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.5: ROW Dual Orexin Receptor Antagonist Market
  • 4.5.1: ROW Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.5.2: ROW Market by Application: Hospital & Clinic, Retail Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Type
  • 6.1.2: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Application
  • 6.1.3: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Region
• 6.2: Emerging Trends in the Global Dual Orexin Receptor Antagonist Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Dual Orexin Receptor Antagonist Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dual Orexin Receptor Antagonist Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Eisal
• 7.3: Idorsia
• 7.4: Takeda